Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07181681 · ClinicalTrials.gov registry record · Phase 1

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Solid Tumors, sponsored by BeOne Medicines.

Recruiting
Registry status
Phase 1
Development phase
63
Enrollment target
8
Study locations

NCT07181681 is a Phase 1 study of Advanced Solid Tumor and Solid Tumors that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 63 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (67% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07181681, a Phase 1 study of Advanced Solid Tumor and Solid Tumors, is actively recruiting participants, sponsored by BeOne Medicines.

RECRUITING
Registry status
Phase 1
Development phase
63 participants
Enrollment target
8
Study locations

Study Summary

This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugated via an enzymatically cleavable linker to a topoisomerase 1 (TOPO1) inhibitor payload. The study aims to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C0902 in participants with advanced solid tumors. The study will be conducted in 2 phases: Phase 1a (dose escalation and safety expansion) and Phase 1b (dose expansion).

Conditions Studied

Advanced Solid Tumor Solid Tumors

Interventions

  • DRUG BG-C0902

Study Locations (8)

Texas

  • The University of Texas Md Anderson Cancer Center - Houston
  • Next Oncology - San Antonio

Victoria

  • Monash Health - Clayton
  • The Alfred Hospital - Melbourne

Virginia

  • Next Virginia - Fairfax

New South Wales

  • Blacktown Cancer and Haematology Centre - Blacktown

Fujian

  • The First Affiliated Hospital of Xiamen University - Xiamen

Zhejiang

  • Zhejiang Cancer Hospital - Hangzhou

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2025-11-10
Est. Completion 2027-11-01
Phase Phase 1

Sponsor

BeOne Medicines

29 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07181681

The ClinicalTrials.gov registry entry for NCT07181681 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (67% lower). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which BG-C0902 is the first listed.

NCT07181681 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Texas, Victoria, Virginia.

Frequently Asked Questions

What is clinical trial NCT07181681 about?

NCT07181681 is a clinical study titled "A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors". This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugated via an enzymatically cleavable linker to a topoisomerase 1 (TOPO1) inhibitor payload. The study ai...

What is the current status of trial NCT07181681?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2025-11-10. Estimated completion is 2027-11-01.

What conditions does trial NCT07181681 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Solid Tumors.

What interventions are being tested in trial NCT07181681?

The interventions under investigation include: BG-C0902 (DRUG).

Who is sponsoring clinical trial NCT07181681?

This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07181681 being conducted?

This trial has 8 study locations across Texas, Virginia, New South Wales, Victoria, Fujian. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Solid Tumors

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.